Alnylam Pharmaceuticals (STU:DUL) Long-Term Debt : €940 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Long-Term Debt?

Alnylam Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2024 was €940 Mil.

Alnylam Pharmaceuticals's quarterly Long-Term Debt declined from Sep. 2023 (€956 Mil) to Dec. 2023 (€936 Mil) but then increased from Dec. 2023 (€936 Mil) to Mar. 2024 (€940 Mil).

Alnylam Pharmaceuticals's annual Long-Term Debt increased from Dec. 2021 (€598 Mil) to Dec. 2022 (€960 Mil) but then declined from Dec. 2022 (€960 Mil) to Dec. 2023 (€936 Mil).

Alnylam Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Alnylam Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Long-Term Debt Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

157.23

597.99

959.99

936.05

Alnylam Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															950.71	940.39	955.56	936.05	939.99

Alnylam Pharmaceuticals (STU:DUL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Alnylam Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (STU:DUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (STU:DUL) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (STU:DUL) Headlines

No Headlines